Outlook Therapeutics $2.24. Huge potential upside.
Outlook Therapeutics are a bio drug company specialising in treating a progressive eyesight problem that affects millions of elderly people worldwide. The disease is called wet macular degeneration.
Outlook have been given approval in Europe and the uk for their new treatment and plan to sell the treatment in these markets in the first half of 2025.
Outlook’s application for FDA approval was postponed last December, they were asked to provide more information, the company says they are continuing the trial and plan to resubmit in the first quarter for FDA approval.
If Outlook get approval, one post on the wires suggests that this is likely, the price will fly.
There is only one other treatment currently available for this disease that affects 20 Million people in the USA.
Outlook have been given approval in Europe and the uk for their new treatment and plan to sell the treatment in these markets in the first half of 2025.
Outlook’s application for FDA approval was postponed last December, they were asked to provide more information, the company says they are continuing the trial and plan to resubmit in the first quarter for FDA approval.
If Outlook get approval, one post on the wires suggests that this is likely, the price will fly.
There is only one other treatment currently available for this disease that affects 20 Million people in the USA.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.